Foster City News
-
Visa Inc. sued Wal-Mart Stores Inc. in a bid to stop the world’s largest retailer from bringing price-fixing claims over merchant swipe fees.
-
AbbVie Inc. said it can win the race against Gilead Sciences Inc. to bring to market a new generation of all-oral hepatitis C drugs.
-
Gilead Sciences Inc.’s Viread pill reduced the risk of injected-drug users contracting the AIDS virus by half in a study in Thailand, a finding that may give public health officials a new weapon to fight HIV’s spread.
-
Gilead Sciences Inc., the world’s largest maker of HIV medicines, said its experimental hepatitis C pill, sofosbuvir, will receive a priority marketing review by U.S. regulators.
-
Jean-Michel Pawlotsky has déjà vu.
-
Takeda Pharmaceutical Co., Asia’s largest drugmaker, sued to block Impax Laboratories Inc. and Novartis AG’s Sandoz unit from selling generic versions of the acid-reflux drug Dexilant.
-
Wal-Mart Stores Inc. and Costco Wholesale Corp., among more than 500 merchants objecting to a $7.25 billion antitrust settlement with credit card firms over swipe fees, say the deal is meaningless as long as card companies can fix fees charged retailers on each transaction.
-
JPMorgan Chase & Co., the largest U.S. lender, named Barry Sommers chief executive officer of its consumer bank, replacing Ryan McInerney, who’s leaving to become president of Visa Inc.
-
Visa Inc. and MasterCard Inc. sued trade groups and retailers that rejected a $7.25 billion settlement in a price-fixing suit and asked a court to rule that the card companies’ fee practices weren’t illegal.
-
Target Corp. and Macy’s Inc. joined with 15 other retailers in suing Visa Inc. and MasterCard Inc. over credit-card and debit-card fees after dropping out of a multibillion-dollar settlement of a similar case.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page